BACKGROUND: Biomarkers can improve clinical trial efficiency, but designing and interpreting biomarker-driven trials require knowledge of relationships among biomarkers, clinical covariates, and endpoints. We investigated these relationships across genomic subgroups of glioblastoma (GBM) within our institution (DF/BWCC), validated results in The Cancer Genome Atlas (TCGA), and demonstrated potential impacts on clinical trial design and interpretation. METHODS: We identified genotyped patients at DF/BWCC, and clinical associations across 4 common GBM genomic biomarker groups were compared along with overall survival (OS), progression-free survival (PFS), and survival post-progression (SPP). Significant associations were validated in TCGA. Biomarker-based clinical trials were simulated using various assumptions. RESULTS: Epidermal growth factor receptor (EGFR)(+) and p53(-) subgroups were more likely isocitrate dehydrogenase (IDH) wild-type. Phosphatidylinositol-3 kinase (PI3K)(+) patients were older, and patients with O6-DNA methylguanine-methyltransferase (MGMT)-promoter methylation were more often female. OS, PFS, and SPP were all longer for IDH mutant and MGMT methylated patients, but there was no independent prognostic value for other genomic subgroups. PI3K(+) patients had shorter PFS among IDH wild-type tumors, however, and no DF/BWCC long-term survivors were either EGFR(+) (0% vs 7%, P = .014) or p53(-) (0% vs 10%, P = .005). The degree of biomarker overlap impacted the efficiency of Bayesian-adaptive clinical trials, while PFS and OS distribution variation had less impact. Biomarker frequency was proportionally associated with sample size in all designs. CONCLUSIONS: We identified several associations between GBM genomic subgroups and clinical or molecular prognostic covariates and validated known prognostic factors in all survival periods. These results are important for biomarker-based trial design and interpretation of biomarker-only and nonrandomized trials.
BACKGROUND: Biomarkers can improve clinical trial efficiency, but designing and interpreting biomarker-driven trials require knowledge of relationships among biomarkers, clinical covariates, and endpoints. We investigated these relationships across genomic subgroups of glioblastoma (GBM) within our institution (DF/BWCC), validated results in The Cancer Genome Atlas (TCGA), and demonstrated potential impacts on clinical trial design and interpretation. METHODS: We identified genotyped patients at DF/BWCC, and clinical associations across 4 common GBM genomic biomarker groups were compared along with overall survival (OS), progression-free survival (PFS), and survival post-progression (SPP). Significant associations were validated in TCGA. Biomarker-based clinical trials were simulated using various assumptions. RESULTS: Epidermal growth factor receptor (EGFR)(+) and p53(-) subgroups were more likely isocitrate dehydrogenase (IDH) wild-type. Phosphatidylinositol-3 kinase (PI3K)(+) patients were older, and patients with O6-DNA methylguanine-methyltransferase (MGMT)-promoter methylation were more often female. OS, PFS, and SPP were all longer for IDH mutant and MGMT methylated patients, but there was no independent prognostic value for other genomic subgroups. PI3K(+) patients had shorter PFS among IDH wild-type tumors, however, and no DF/BWCC long-term survivors were either EGFR(+) (0% vs 7%, P = .014) or p53(-) (0% vs 10%, P = .005). The degree of biomarker overlap impacted the efficiency of Bayesian-adaptive clinical trials, while PFS and OS distribution variation had less impact. Biomarker frequency was proportionally associated with sample size in all designs. CONCLUSIONS: We identified several associations between GBM genomic subgroups and clinical or molecular prognostic covariates and validated known prognostic factors in all survival periods. These results are important for biomarker-based trial design and interpretation of biomarker-only and nonrandomized trials.
Authors: Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin Journal: Cell Date: 2013-10-10 Impact factor: 41.582
Authors: Pierre Bady; Davide Sciuscio; Annie-Claire Diserens; Jocelyne Bloch; Martin J van den Bent; Christine Marosi; Pierre-Yves Dietrich; Michael Weller; Luigi Mariani; Frank L Heppner; David R Mcdonald; Denis Lacombe; Roger Stupp; Mauro Delorenzi; Monika E Hegi Journal: Acta Neuropathol Date: 2012-07-19 Impact factor: 17.088
Authors: Shakti H Ramkissoon; Wenya Linda Bi; Steven E Schumacher; Lori A Ramkissoon; Sam Haidar; David Knoff; Adrian Dubuc; Loreal Brown; Margot Burns; Jane B Cryan; Malak Abedalthagafi; Yun Jee Kang; Nikolaus Schultz; David A Reardon; Eudocia Q Lee; Mikael L Rinne; Andrew D Norden; Lakshmi Nayak; Sandra Ruland; Lisa M Doherty; Debra C LaFrankie; Margaret Horvath; Ayal A Aizer; Andrea Russo; Nils D Arvold; Elizabeth B Claus; Ossama Al-Mefty; Mark D Johnson; Alexandra J Golby; Ian F Dunn; E Antonio Chiocca; Lorenzo Trippa; Sandro Santagata; Rebecca D Folkerth; Philip Kantoff; Barrett J Rollins; Neal I Lindeman; Patrick Y Wen; Azra H Ligon; Rameen Beroukhim; Brian M Alexander; Keith L Ligon Journal: Neuro Oncol Date: 2015-03-09 Impact factor: 12.300
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee Journal: Genes Dev Date: 2007-11-01 Impact factor: 11.361
Authors: D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler Journal: Science Date: 2008-09-04 Impact factor: 47.728
Authors: Justin M Craig; Natalie Vena; Shakti Ramkissoon; Ahmed Idbaih; Shaun D Fouse; Memet Ozek; Aydin Sav; D Ashley Hill; Linda R Margraf; Charles G Eberhart; Mark W Kieran; Andrew D Norden; Patrick Y Wen; Massimo Loda; Sandro Santagata; Keith L Ligon; Azra H Ligon Journal: PLoS One Date: 2012-06-15 Impact factor: 3.240
Authors: Daniel N Cagney; Joohee Sul; Raymond Y Huang; Keith L Ligon; Patrick Y Wen; Brian M Alexander Journal: Neuro Oncol Date: 2018-08-02 Impact factor: 12.300
Authors: Patrick J Cimino; Lisa McFerrin; Hans-Georg Wirsching; Sonali Arora; Hamid Bolouri; Raul Rabadan; Michael Weller; Eric C Holland Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300
Authors: Patrick J Cimino; Courtney Ketchum; Rust Turakulov; Omkar Singh; Zied Abdullaev; Caterina Giannini; Peter Pytel; Giselle Yvette Lopez; Howard Colman; MacLean P Nasrallah; Mariarita Santi; Igor Lima Fernandes; Jeff Nirschl; Sonika Dahiya; Stewart Neill; David Solomon; Eilis Perez; David Capper; Haresh Mani; Dario Caccamo; Matthew Ball; Michael Badruddoja; Rati Chkheidze; Sandra Camelo-Piragua; Joseph Fullmer; Sanda Alexandrescu; Gabrielle Yeaney; Charles Eberhart; Maria Martinez-Lage; Jie Chen; Leor Zach; B K Kleinschmidt-DeMasters; Marco Hefti; Maria-Beatriz Lopes; Nicholas Nuechterlein; Craig Horbinski; Fausto J Rodriguez; Martha Quezado; Drew Pratt; Kenneth Aldape Journal: Acta Neuropathol Date: 2022-10-22 Impact factor: 15.887
Authors: Stephen J Bagley; Jacob Till; Aseel Abdalla; Hareena K Sangha; Stephanie S Yee; Jake Freedman; Taylor A Black; Jasmin Hussain; Zev A Binder; Steven Brem; Arati S Desai; Donald M O'Rourke; Qi Long; Seyed Ali Nabavizadeh; Erica L Carpenter Journal: Neurooncol Adv Date: 2021-01-16